BioSpace News Archive

Covalon Technologies Ltd. today announced that its Board of Directors (the “ Board ”) has appointed Mr. Brent Ashton to serve as Chief Executive Officer and a director of the Company, effective immediately.

Aldeyra Therapeutics, Inc. today announced advancement of its RASP modulator platform, including the expected submission to the FDA of a proposed expansion of the Phase 2 clinical trial of the investigational RASP modulator ADX-629.

ADC Therapeutics SA today announced that it received a notice from the New York Stock Exchange (NYSE) on January 2, 2024 that the Company has regained compliance with the continued listing minimum price criteria set forth in Section 802.01C of the NYSE Listed Company Manual and, as a result, will be removed from the NYSE’s noncompliant issuers list.

Sensei Biotherapeutics, Inc. today provided corporate updates on its research and development programs and upcoming milestones.

Soligenix, Inc. announced today preliminary top-line results of its ongoing Phase 2a trial of SGX302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis.

ZyVersa Therapeutics, Inc. announces that Noble Capital Markets has initiated company-sponsored equity research coverage.

Enara Bio today announces that Boehringer Ingelheim has exercised its option to license a number of cancer antigens discovered and validated through the ongoing collaboration using Enara Bio’s Dark Antigen discovery platform, EDAPT®.

Reviva Pharmaceuticals Holdings, Inc., a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system, inflammatory and cardiometabolic diseases, provided program updates and announced upcoming key milestones.

Solid Biosciences Inc. today announced that Bo Cumbo, President and Chief Executive Officer, will present at the J.P Morgan Healthcare Conference on Thursday, January 11, 2024, at 9:45 am PT.

Cocrystal Pharma, Inc. provides an update on the clinical development of its oral first-in-class pan-norovirus and pan-coronavirus dual protease inhibitor CDI-988 and its oral PB2 inhibitor CC-42344 for the treatment of pandemic and seasonal influenza A.